Study of ANA773 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)

Part A Inclusion: * Male or female, ages 18 to 65 years * No clinically significant abnormalities * No serious or severe chronic conditions * Non-smokers Part A Exclusion: * Female subjects who are pregnant or breast-feeding * History of significant medical condition that could interfere with study medication or associated study assessments * History of or current drug or alcohol abuse Part B Inclusion Criteria: * Male or female, ages 18 to 65 years * Diagnosed with chronic liver disease consistent with chronic hepatitis C infection for at least 6 months * Screening HCV RNA ≥ 375,000 copies/mL or ≥ 75,000 IU/mL * Naïve to or have relapsed from prior IFN-alpha based therapy Part B Exclusion Criteria: * Female subjects who are pregnant or breast-feeding * Received anti-viral therapy or immunomodulatory therapy within 90 days prior to administration of the first dose of study medication * Use of an investigational drug or participation in an investigational study with a licensed drug within 30 days * History of significant medical condition that could interfere with study medication or associated study assessments * History of or current drug or alcohol abuse